An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions

Autor: Catherine Lomen-Hoerth, Gary L. Pattee, Andrea E. Formella, James Wymer, Stanley H. Appel, Laura E. Pope

Publikováno v: Lomen-Hoerth, Catherine; Pattee, GL; Wymer, JP; Appel, SH; Formella, AE; & Pope, LE. (2014). An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/99t8g4z1
Current Medical Research and Opinion

Background: Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient’s emoti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef3e7badd86432f5ee6e64ecf7ada3a4

Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use

Autor: Laura E. Pope, Stephen F. Traynelis, Charles P. Taylor, Rae R. Matsumoto, Joao Siffert

Publikováno v: Pharmacology & Therapeutics. 164:170-182

Dextromethorphan (DM) has been used for more than 50years as an over-the-counter antitussive. Studies have revealed a complex pharmacology of DM with mechanisms beyond blockade of N-methyl-d-aspartate (NMDA) receptors and inhibition of glutamate exci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a7312739a4a7acc78a03bd7117cd560
https://doi.org/10.1016/j.pharmthera.2016.04.010

A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers

Autor: Cynthia Bartlett, Laura E. Pope, Kerri A. Schoedel, Edward M. Sellers

Publikováno v: Clinical Drug Investigation

Background and Objective: Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f408a2f2a1c0252643e25c83cf6bfb5
https://doi.org/10.1007/bf03261905

Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study

Autor: Laura E. Pope, Ronald A. Thisted, Aziz Shaibani, Adrian Hepner

Publikováno v: Pain Medicine. 13:243-254

Objective. To evaluate dextromethorphan coadministered with quinidine as treatment of diabetic peripheral neuropathic pain. Design. In a 13-week, phase 3, randomized controlled trial, 379 adults with daily symmetric diabetic peripheral neuropathy (DP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5676fc0b1431a04948386111ce52a1
https://doi.org/10.1111/j.1526-4637.2011.01316.x

Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: A 29-day, multicenter, open-Label, dose-escalation study

Autor: Ronald A. Thisted, Neil W. Culligan, James Wymer, Gary Gerard, Leslie Klaff, Sherwyn L. Schwartz, Laura E. Pope, James Berg

Publikováno v: Clinical Therapeutics. 28:1607-1618

Background: Pain associated with diabetic peripheral neuropathy (DPN) has a substantial negative impact on patients' quality of life. Objectives: The primary objective of this study was to evaluate the tolerability of capsules containing dextromethor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8649c61dba80c1f0c3ea07ace8d6ac59
https://doi.org/10.1016/j.clinthera.2006.10.005